Compare IDEXX Laboratories, Inc. (IDXX) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Match Group Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Match Group Inc trades at $36.82 (market cap $8.45B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.5× Match Group Inc's market cap, and Match Group Inc pays a 2.17% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MTCH | |
|---|---|---|
Market Cap | $46.22B | $8.45B |
Sector | Health | Media |
52-Week High | $766.68 | $41.24 |
52-Week Low | $526.44 | $28.90 |
Enterprise Value | $47.12B | $11.42B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Match Group (MTCH) trades at $36.63, down 0.27% with bearish technical signals despite reasonable valuation metrics (P/E 13.05, P/S 2.66). Recent Q2 2026 earnings missed revenue estimates with $853 million (down 1% YoY) though Tinder engagement improved and Hinge grew 22% YoY. Operating cash flow remains strong at $1.08 billion in 2025, but high debt ($3.85 billion) and negative shareholder equity pose balance sheet concerns.
The outlook is mixed: analyst consensus is Buy (53% of 32 analysts) with $42.33 price target (16% upside), but near-term revenue pressure and Tinder's sluggish performance create headwinds. Investment opportunity lies in Hinge's international expansion and Tinder turnaround potential, while risks include execution missteps, competitive threats, and macroeconomic sensitivity affecting dating app usage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
